Stem cell memory EBV-specific T cells control post-transplant lymphoproliferative disease and persist in vivo
Palianina, D.; Mietz, J.; Stuehler, C.; Arnold, B.; Bantug, G. R.; Münz, C.; Chijioke, O.; Khanna, N.
Show abstract
Adoptive T cell therapy (ACT), the therapeutic transfer of defined T cell immunity to patients, offers great potential in the fight against different human diseases including difficult-to-treat viral infections but response rates are still suboptimal. Very early differentiated stem cell memory T cells (TSCM) have superior self-renewal, engraftment, persistence, and anti-cancer efficacy, but their potential for anti-viral ACT remains unknown. Here, we developed a clinically-scalable protocol for expanding Epstein-Barr virus (EBV)-specific TSCM-enriched T cells with high proportions of CD4+ T cells and broad EBV antigen coverage. These cells showed tumor control in a xenograft model of post-transplant lymphoproliferative disorder (PTLD) and were superior to previous ACT protocols in terms of tumor infiltration, in vivo proliferation, persistence, proportion of functional CD4+ T cells, and diversity of EBV antigen specificity. Thus, our new protocol may pave the way for the next generation of potent unmodified antigen-specific cell therapies for EBV-associated diseases, including tumors, and other indications.
Matching journals
The top 13 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Affinity-matured CD72-targeting Nanobody CAR T-cells Enhance Elimination of Antigen-Low B-cell Malignancies 96%
- A Mimicry-Based Strategy Between Human and Commensal Antigens for the Development of a New Family of Immune Therapies for Cancer 96%
- Tumor-Specific CD8+ T Cells from the Bone Marrow Resist Exhaustion and Exhibit Increased Persistence in Tumor-Bearing Hosts as Compared to Tumor Infiltrating Lymphocytes 95%
Similar papers in this journal
Similar papers in this journal
- Pre-conditioning Modifies the Tumor Microenvironment to Enhance Solid Tumor CAR T Cell Efficacy and Endogenous Immunity 95%
- CD33 Epitope Editing Unlocks UM171-Expanded Cord Blood Grafts for AML Immunotherapy 93%
- Augmenting TCR signal strength and ICOS costimulation results in metabolically fit and therapeutically potent human CAR Th17 cell therapy 93%
Similar papers in this journal
- Single-cell profiling identifies a spectrum of human unconventional intraepithelial T lineage cells 95%
- Cell-intrinsic functions of the transcription factor Bhlhe40 in activated B cells and T follicular helper cells restrain the germinal center reaction and prevent lymphomagenesis 94%
- HDAC1 controls the generation and maintenance of effector-like CD8+ T cells during chronic viral infection 94%
Similar papers in this journal
- Neoantigen Cancer Vaccines and Different Immune Checkpoint Therapies Each Utilize Both Converging and Distinct Mechanisms that in Combination Enable Synergistic Therapeutic Efficacy 96%
- Generation of glucocorticoid resistant SARS-CoV-2 T-cells for adoptive cell therapy 95%
- Cell therapy with IL-10-producing group 2 innate lymphoid cells suppresses Graft-versus-Host disease 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.